MCP, TLX, AHUS2, MIC10, TRA2.10, MGC26544, complement regulatory protein, trophoblast leucocyte common antigen

For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

Mouse IgG1

Mouse

1 ml (100 ug/ml) 0.2 um filtered antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide.

Product should be stored at 4 degree C. Under recommended storage conditions, product is stable for one year.

Small volumes of anti-CD46 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Product Description: The monoclonal antibody M177 recognizes CD46, also designated membrane cofactor protein (MCP). CD46 is a 45-70 kDa protein with genetic and tissue-specific heterogeneity.- It is expressed on every cell and tissue, with the exception of erythrocytes. CD46 serves to inhibit complement activation on host tissue. It performs this function by serving as a cofactor which binds to C3b and C4b. This binding is permitted by factor I, a serine protease of plasma, to degrade C3b and C4b and serves to protect the host cell against autologous attack. It also serves as a receptor for measles virus.
Four isoforms of CD46 predominate and arise by alternative splicing of a single CD46 gene. CD46 cDNA encodes a signal sequence followed by four complement control protein domains (also called short consensus repeats (SCR)). The monoclonal antibody M177 reacts with the SCR2 domain

Flow Cytometry (FC/FACS), FS, Immunoassay (IA), Immunoprecipitation (IP), Western Blot (WB)

Application Notes: FC: Antibody M177 stains the extracellular domain of CD46.
Application Use: For immunohistology, flow cytometry and Western blotting dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10. For inhibition of biological activity in vitro dilutions have to be made according to the amounts of CD46 to be inactivated.

36,826 Da

CD46 molecule, complement regulatory protein

membrane cofactor protein; measles virus receptor; complement membrane cofactor protein; trophoblast leucocyte common antigen; trophoblast leukocyte common antigen; CD46 antigen, complement regulatory protein; trophoblast-lymphocyte cross-reactive antigen; antigen identified by monoclonal antibody TRA-2-10; membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive antigen)

Membrane cofactor protein

MCP; MIC10??[Similar Products]

MCP_HUMAN

The protein encoded by this gene is a type I membrane protein and is a regulatory part of the complement system. The encoded protein has cofactor activity for inactivation of complement components C3b and C4b by serum factor I, which protects the host cell from damage by complement. In addition, the encoded protein can act as a receptor for the Edmonston strain of measles virus, human herpesvirus-6, and type IV pili of pathogenic Neisseria. Finally, the protein encoded by this gene may be involved in the fusion of the spermatozoa with the oocyte during fertilization. Mutations at this locus have been associated with susceptibility to hemolytic uremic syndrome. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jun 2010]

CD46: Acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement- mediated injury by cleaving C3b and C4b deposited on host tissue. May be involved in the fusion of the spermatozoa with the oocyte during fertilization. Also acts as a costimulatory factor for T- cells which induces the differentiation of CD4+ into T-regulatory 1 cells. T-regulatory 1 cells suppress immune responses by secreting interleukin-10, and therefore are thought to prevent autoimmunity. A number of viral and bacterial pathogens seem to exploit this property and directly induce an immunosuppressive phenotype in T-cells by binding to CD46. Defects in CD46 are a cause of susceptibility to hemolytic uremic syndrome atypical type 2 (AHUS2). An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Patients with CD46 mutations seem to have an overall better prognosis compared to patients carrying CFH mutations. 16 isoforms of the human protein are produced by alternative splicing.

Protein type: Receptor, misc.; Membrane protein, integral; Cell surface

Chromosomal Location of Human Ortholog: 1q32

Cellular Component: Golgi apparatus; inner acrosomal membrane; focal adhesion; cell surface; basolateral plasma membrane; integral to plasma membrane; plasma membrane

Molecular Function: enzyme inhibitor activity; complement binding; protein binding; cadherin binding; endopeptidase activity; receptor activity

Biological Process: positive regulation of memory T cell differentiation; adaptive immune response; positive regulation of regulatory T cell differentiation; regulation of Notch signaling pathway; viral reproduction; negative regulation of complement activation; T cell mediated immunity; single fertilization; negative regulation of catalytic activity; regulation of complement activation; interleukin-10 production; innate immune response; positive regulation of T cell proliferation; proteolysis; complement activation, classical pathway; positive regulation of interleukin-10 production

1. Seya, T et al; Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation. J Immunol 1990, 145: 238
2. Iwata, K et al; Diversity of sites for measles virus binding and for inactivation of complement C3b and C4b on membrane cofactor protein CD46. J Biol Chem 1995, 270: 15148
3. Kurita-Taniguchi, M et al; Functional modulation of human macrophages through CD46 (Measles virus receptor): production of IL-12 p40 and nitric oxide in association with recruitment of proteintyrosine phosphatase SHP-1 to CD46. J Immunol 2000, 165: 5143
4. Kurita-Taniguchi, M et al; Molecular assembly of CD46 with CD9, alpha3-beta1 integrin and protein tyrosine phosphatase SHP-1 in human macrophages through differentation by GM-CSF. Mol Immunol 2001, 38: 689
5. Lor?, K et al; Myeloid and plasmacytoid dentritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 2007, 179: 1721
6. Kato, S et al. Reduced ability of hemagglutinin of the the CAM-70 measles virus vaccine strain to use receptors CD46 and SLAM. Vaccine 2009, 27:3838
7. Matsui, H et al. Enhanced transduction efficiency of fiber-substituted adenovirus vectors by the incorporation of RGD peptides in two distict regions of the adenovirus serotype 35 fiber knob. Virus research 2010, doi10.1016/j.virusres.2010.08.021

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.